News

Multimodal DCIS Therapy, Tamoxifen Cuts Breast Cancer Deaths

Publish date: October 5, 2011

 

FROM THE ANNUAL MEETING OF THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY

The meta-analysis was internally funded. Dr. Stuart reported having no relevant financial disclosures. Dr. Wong’s study was funded by participating institutions. Dr. Wong reported no other relevant financial disclosures.

Pages

Recommended Reading

Commentary: Depression Stymies Care in Latina Breast Cancer Survivors
MDedge Hematology and Oncology
Taxane-Induced Neuropathy Gives No Clue to Breast Cancer Outcomes
MDedge Hematology and Oncology
Stress May Factor Into Breast Tumor Aggressiveness
MDedge Hematology and Oncology
MRI Breast Screening Effective for Underserved Women
MDedge Hematology and Oncology
Score Predicts Late Recurrence in ER-Positive Breast Cancer
MDedge Hematology and Oncology
Chemo Timing Does Not Affect Breast Cancer Recurrence
MDedge Hematology and Oncology
Trastuzumab-Based T-DM1 Delays Breast Cancer Progression
MDedge Hematology and Oncology
Everolimus Posts Big Win in ER-Positive Breast Cancer
MDedge Hematology and Oncology
Prone Position During Breast Irradiation Lessens Lung Cancer Risk
MDedge Hematology and Oncology
California Insurer Drops Bevacizumab Breast Cancer Coverage
MDedge Hematology and Oncology